ReviewBiotechnologia2025
Delivery and adjuvant: liposomes for SARS-CoV-2 vaccines.
Review in Biotechnologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy Assessment of Montanide GEL 02 PR and Liposome-Based Encapsulation as Adjuvants for an FrpA Subunit Vaccine Against Photobacteriosis in Solea senegalensis.Journal of fish diseases · 2026Article
- Engineering Liposomes and Polymer Conjugates: A Platform for Mechanistic Complement Activation Studies and Controlled Release Applications.ACS applied materials & interfaces · 2026Article
- Acne vaccine targetingBiotechnologia · 2026Article
- Effect of PEI25k/DOTAP/cholesterol liposomal formulation on the immunogenicity of SARS-CoV-2 spike protein-encoding DNA vaccine.Biotechnologia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global COVID-19 pandemic has highlighted the critical role of vaccines in controlling infectious diseases, with liposome-based formulations emerging as a pivotal advancement in vaccine technology. Liposomes are spherical vesicles composed of lipid bilayers that serve as drug delivery systems and versatile adjuvants, enhancing vaccine efficacy through improved antigen stability, targeted delivery, and immunogenicity. This review explores the potential of liposomes as adjuvants in both mRNA and protein subunit SARS-CoV-2 vaccines, detailing their composition and dual impact on innate and adaptive immune responses. Notably, liposome-based mRNA vaccines, such as those developed by Pfizer and Moderna, have demonstrated high efficacy by utilizing lipid nanoparticles to encapsulate mRNA and stimulate antigen-presenting cells, thereby inducing robust immune responses. Despite their advantages, challenges remain, including the optimization of lipid compositions and the mitigation of adverse immune effects. This review also examines the broad applications of liposomes in nanomedicine - from cancer therapy to antifungal treatments - and their potential for future vaccine development. By bridging the gap between engineering and immunology, the study of liposomes underscores their transformative potential in addressing current and emerging global health challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.